NCT07654842
Fasenra: An Asthma Study
Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatmentEndeavor HealthInvestigator-initiated
~40 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:Budesonide-albuterolBenralizumab
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in anti-inflammatory reliever inhaler use during last benralizumab dosing cycle
Measured over Weeks 17 through 24
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Giselle Mosnaim, MD, MS · PRINCIPAL_INVESTIGATOR · Endeavor Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Exclusion
Use of systemic corticosteroids for at least 3 consecutive days (or a single depo-injectable dose of corticosteroids)
An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma
An emergency department visit (defined as evaluation and treatment for \<24 hours in an emergency department or urgent care) due to asthma that required systemic corticosteroids (as per above) 5. Current enrollment in an asthma-related clinical trial. 6. Any known history of adverse reactions to budesonide-albuterol.
What this trial measures
- Change in anti-inflammatory reliever inhaler use during last benralizumab dosing cycleWeeks 17 through 24
Difference between ICS-SABA uses in the first and last two weeks of the 3rd of 3 benralizumab dosing cycles during the study period.